PV Bulletin

Nature's Own Glucosamine Sulfate with Chondroitin and Nature's Own Magnesium Glycinate 1150mg Recall by Sanofi Consumer Healthcare

Sanofi Consumer Healthcare recalls Nature's Own Glucosamine Sulfate with Chondroitin (320 pack) and Nature's Own Magnesium Glycinate 1150mg (300 pack) due to potential presence of glass fragments in the bottle.

Primary source: https://www.tga.gov.au/safety/recalls-and-other-market-actions/market-actions/natures-own-glucosamine-sulfate-chondroitin-and-natures-own-magnesium-glycinate-1150mg

PV Impact Brief

Urgency: HighConfidence: high

What changed

Recall initiated for Nature's Own Glucosamine Sulfate with Chondroitin (batch 1662937) and Nature's Own Magnesium Glycinate 1150mg (batch 1665576) due to glass fragments.

Why it matters

Glass fragments can cause injury when handling product or harm if accidentally swallowed, requiring immediate consumer action.

Action needed

Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

one-time

Regulatory action details

Action type
Recall
Publication date
2026-06-03
Safety issue
Recall due to the potential presence of glass fragments in specific batches of supplements.

Affected products

  • Nature's Own Glucosamine Sulfate with Chondroitin
    Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare
  • Nature's Own Magnesium Glycinate 1150mg
    Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare
    1665576

PV internal implications

Consumers should stop using the product and return it to the place of purchase for a full refund.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 3, 2026

Full briefing

Practical implication

Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.

Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare is recalling two products due to potential glass fragments in the bottle, posing cut and ingestion hazards.

What changed: Recall initiated for Nature's Own Glucosamine Sulfate with Chondroitin (batch 1662937) and Nature's Own Magnesium Glycinate 1150mg (batch 1665576) due to glass fragments.

Why it matters: Glass fragments can cause injury when handling product or harm if accidentally swallowed, requiring immediate consumer action.

Practical implication: Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#Recalls#Recall#Therapeutic Goods Administration (TGA)#safety_signal#firecrawl-agent#regulatory-extraction

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward